# TriAgenics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triagenics

- Industry: Medical Devices & Equipment
- Headquarters: Redmond, US
- Website: www.triagenics.com
- Total disclosed funding: $3.5M
- Latest round: Series B (Sep 11, 2025)
- Investors on record: 1

## About

TriAgenics, Inc. is a dental technology company focused on innovative solutions to prevent wisdom teeth formation, enhancing patient care through non-invasive procedures. Founded in 2017 in Redmond, US, TriAgenics, Inc. specializes in dental technology aimed at preventing wisdom teeth complications. In September 2025, TriAgenics, Inc. raised USD 500,000 in series B funding from returning investor Asclepius Ventures LLC. TriAgenics, Inc. specializes in innovative dental technology, specifically focused on the prevention of wisdom teeth formation through their flagship product, the Zero3™ TBA (3rd Molar Tooth Bud Ablation). This minimally invasive procedure is designed to gently warm the developing wisdom tooth buds, effectively blocking their formation within a treatment window of 60 to 90 seconds. The core offering aims to provide a simpler, safer alternative to traditional wisdom tooth extraction, thereby addressing the common dental issue of third molar complications. The company primarily targets dental professionals and oral surgeons, intending to enhance patient care by reducing the need for surgical interventions. Although the current market for this technology is primarily within North America, there is potential for expansion into other regions as awareness and acceptance of this innovative treatment grow.TriAgenics, Inc. generates revenue through the commercialization of its Zero3™ TBA procedure within the dental industry, primarily engaging in business-to-business transactions with dental practices and oral surgical centers. The revenue model is based on direct sales of the treatment procedure, which is anticipated to be integrated into existing dental practices' service offerings. Pricing structures are designed to reflect the value of the innovative treatment while considering the operational costs dental professionals encounter when providing care. The company's strategy includes establishing partnerships with dental equipment suppliers to facilitate broader distribution and adoption among end-users, which are primarily dental practitioners serving patients with wisdom teeth issues. With its focus on pioneering dental solutions, TriAgenics aims to build a sustainable revenue stream through the continued development and promotion of its proprietary technology. The company plans to utilize the September 2025 funding to help secure clearance from the U.S. Food and Drug Administration for its Zero3 TBA system.

## Funding rounds

- Series B, Sep 11, 2025, $0.5M — Asclepius Ventures
- Series B, Jul 16, 2025, $3M — Asclepius Ventures

## Investors

- Asclepius Ventures (https://capitalatlas.ai/funds/asclepius-ventures) — Series B